Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
novartis
5
×
roche
5
×
san francisco top stories
boston blog main
boston top stories
indiana blog main
indiana top stories
national
new york top stories
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
drug prices
genentech
medicare
new york blog main
pfizer
president trump
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
alzheimer's disease
amgen
cancer immunotherapy
What
drug
5
×
bio
patients
roundup
fda
latest
new
plan
therapy
acquisitions
address
advantages
albert
alzheimer’s
approval
approved
approves
atrophy
bar
biggest
blueprint
bourla
brings
cancer
carries
ceo
certain
companies
company
crispr
daily
designed
different
evrysdi
expect
fail
friday
future
gamble
gene
Language
unset
unknown
Current search:
novartis
×
drug
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More